Clinical Trials Browser

INDUSTRY × Myelodysplastic Syndromes × tamibarotene × Clear all

NCT02807558 2024-12-13

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2 Completed

155 enrolled 24 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute